Coherent Biopharma’s another BESTTM（Bi-Engaging ligand-mediated Selective Targeting）platform pipeline investigational drug,...
Coherent Biopharma (CBP) revealed Phase Ia clinical study results of the CBP-1008 in a poster presentation at the 2021 ASCO Annual...
On March 25, 2021, Coherent Biopharma (Suzhou) Co., Ltd. (hereinafter referred to as “Coherent Biopharma”) and Roche Diag...
On December 20, 2020, CBP-1008 Phase Ib trial investigator meeting was held in Beijing, during which heated discussions on clinica...
On October 16, 2020, CBP-1008, a bi-engaging ligand-mediated selective targeting drug conjugate developed by Coherent Biopharma, g...